Stock Events

Stock Events

KalVista Pharmaceuticals 

€16.3
0
-€0.3-1.81% Today

Statistics

Day High
16.4
Day Low
16.3
52W High
18
52W Low
9.05
Volume
0
Avg. Volume
137
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MarExpected
Q3 2025
Q4 2025
-0.8
-0.67
-0.55
-0.42
Expected EPS
-0.58147875222
Actual EPS
-0.4238549

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4XC1.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetically defined diseases, competing in the same rare disease space as KalVista.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals engages in creating small molecule drugs for serious diseases, directly competing with KalVista's approach in drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious diseases, including therapies that could compete with KalVista's portfolio.
Biogen
BIIB
Mkt Cap25.38B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, competing for similar patient populations as KalVista.
AMGEN
AMGN
Mkt Cap189.22B
Amgen develops therapeutics in areas including cardiovascular disease, competing with KalVista's efforts in hereditary angioedema.
Novartis
NVS
Mkt Cap297.35B
Novartis offers a broad range of healthcare products including innovative medicines, directly competing across multiple areas including treatments for diseases targeted by KalVista.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences focuses on antiviral drugs for infectious diseases, but its expansion into other therapeutic areas could position it as a competitor to KalVista.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie works on a broad portfolio of drugs, including efforts in immunology and oncology, areas that could intersect with KalVista's therapeutic targets.

About

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Show more...
CEO
Mr. Benjamin L. Palleiko
Employees
275
Country
United States
ISIN
US4834971032

Listings

MU
DE
4XC1.MU
STU
DE
4XC1.STU
F
DE
4XC1.F
XNAS
US
KALV

0 Comments

Share your thoughts

FAQ

What is KalVista Pharmaceuticals stock price today?▼
The current price of 4XC1.STU is €16.3 EUR — it has decreased by -1.81% in the past 24 hours. Watch KalVista Pharmaceuticals stock price performance more closely on the chart.
What is KalVista Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange KalVista Pharmaceuticals stocks are traded under the ticker 4XC1.STU.
Is KalVista Pharmaceuticals stock price growing?▼
4XC1.STU stock has fallen by -5.2% compared to the previous week, the month change is a +11.56% rise, over the last year KalVista Pharmaceuticals has showed a +57.69% increase.
When is the next KalVista Pharmaceuticals earnings date?▼
KalVista Pharmaceuticals is going to release the next earnings report on September 03, 2026.
What were KalVista Pharmaceuticals earnings last quarter?▼
4XC1.STU earnings for the last quarter are -0.42 EUR per share, whereas the estimation was -0.58 EUR resulting in a +27.11% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does KalVista Pharmaceuticals have?▼
As of April 14, 2026, the company has 275 employees.
In which sector is KalVista Pharmaceuticals located?▼
KalVista Pharmaceuticals operates in the Health & Wellness sector.
When did KalVista Pharmaceuticals complete a stock split?▼
KalVista Pharmaceuticals has not had any recent stock splits.
Where is KalVista Pharmaceuticals headquartered?▼
KalVista Pharmaceuticals is headquartered in Framingham, United States.